We bring you the latest news from the healthcare about the health care in the United Kingdom.

dinsdag 28 november 2017

Nature Reviews Drug Discovery contents December 2017 Volume 16 Number 12 pp 811-883

If you are unable to see the message below, click here to view.
Nature Reviews Drug Discovery

Custom Manufacturing 

The Exact Products You Want: For Your Assays, To Your Specifications, On Your Schedule. Learn about our custom manufacturing capabilities and how we can partner with you to meet your product needs.
December 2017 Volume 16 Number 12 Advertisement
Nature Reviews Drug Discovery cover
2016 2-year Impact Factor 57.000 Journal Metrics 2-year Median 38
In this issue
News and Analysis
Research Highlights
Also this month
 Featured article:
Tau-based therapies in neurodegeneration: opportunities and challenges
Chuanzhou Li & Jürgen Götz


Do you have novel targets for collaborative drug discovery? We could award your lab £100,000

Our translational awards will be made to the PI after the successful review of the project and feasibility in our drug discovery labs. Collaborate with LifeArc, the charity turning great science into greater patient impact.

Visit https://www.lifearc.org/working-with-us/drug-discovery/

Recommend to library
Discover a new path to your success via Human Data Science. IMS Health and Quintiles are now IQVIA™ - created to advance your pursuits of human science by unleashing the power of data science and human ingenuity. We are here to help you find solutions to drive healthcare forward.

Join the journey today.

BioPharma DealmakersCompany Profiles and Partnering Opportunities

Nature Outline: Fatty liver disease 

The worldwide rise in obesity and diabetes has led to a spike in the incidence of non-alcoholic fatty liver disease, which often progresses to the more severe non-alcoholic steatohepatitis. This Outline discusses diagnostic techniques and therapies. 

Access the Outline free online 

Produced with support from: 
Gilead Sciences 
Is your organization planning a scientific event or conference for 2018?

Looking for a way to increase the number of attendees?

Advertise in the Natureevents Directory 2018.

Available online and in print. Ad close deadline: 4 December, 2017
Comment: Legacy data sharing to improve drug safety assessment: the eTOX project
Ferran Sanz, François Pognan, Thomas Steger-Hartmann, Carlos Díaz, Montserrat Cases, Manuel Pastor, Philippe Marc, Joerg Wichard, Katharine Briggs, David K. Watson, Thomas Kleinöder, Chihae Yang, Alexander Amberg, Maria Beaumont, Anthony J. Brookes, Søren Brunak, Mark T. D. Cronin, Gerhard F. Ecker, Sylvia Escher, Nigel Greene, Antonio Guzmán, Anne Hersey, Pascale Jacques, Lieve Lammens, Jordi Mestres, Wolfgang Muster, Helle Northeved, Marc Pinches, Javier Saiz, Nicolas Sajot, Alfonso Valencia, Johan van der Lei, Nico P. E. Vermeulen, Esther Vock, Gerhard Wolber & Ismael Zamora

p811 | doi:10.1038/nrd.2017.177
The sharing of legacy preclinical safety data among pharmaceutical companies and its integration with other information sources offers unprecedented opportunities to improve the early assessment of drug safety. Here, we discuss the experience of the eTOX project, which was established through the Innovative Medicines Initiative to explore this possibility.
Abstract | Full Text | PDF | Supplementary information

Small molecules against RNA targets attract big backers
Asher Mullard

p813 | doi:10.1038/nrd.2017.239
Novartis, Merck, Pfizer and biotech entrepreneurs have started working on small-molecule drugs that act on an assortment of RNA targets, hoping to unlock once undruggable targets and new biology.
Cryo-electron microscopy makes waves in pharma labs
Mark Peplow

p815 | doi:10.1038/nrd.2017.240
Companies hope the Nobel Prize-winning imaging methodology will reveal biomolecule characteristics that can guide drug discovery projects.
FDA approves first digital pill
Asher Mullard

p818 | doi:10.1038/nrd.2017.248
Second anticancer CAR T therapy receives FDA approval
Asher Mullard

p818 | doi:10.1038/nrd.2017.249
BTK inhibitors get a boost
Asher Mullard

p818 | doi:10.1038/nrd.2017.250
Trial watch: Tracing investment in drug development for Alzheimer disease
Alpha Tom Kodamullil, Firas Zekri, Meemansa Sood, Bastian Hengerer, Luc Canard, Duncan McHale & Martin Hofmann-Apitius

p819 | doi:10.1038/nrd.2017.169
Eric Rubin
p820 | doi:10.1038/nrd.2017.228
Eric Rubin, vice president of clinical oncology at Merck & Co, discusses tumour-agnostic approvals, immunotherapy combinations and the modernization of clinical trial eligibility criteria.
The human microbiome: opportunity or hype?
Pedro M. Valencia, Magali Richard, Jesse Brock & Elsy Boglioli

p823 | doi:10.1038/nrd.2017.154
This article discusses investment in microbiome-based therapeutic approaches and key questions for the field related to the underlying science, clinical development, regulation and business models.

Sepsis: Stalking a new target
p825 | doi:10.1038/nrd.2017.238

Metabolic disease: Ectopic olfactory receptor activation reverses obesity
p826 | doi:10.1038/nrd.2017.230

Cancer: Bispecific antibody directs T cells to solid tumours
p826 | doi:10.1038/nrd.2017.237

Obesity: GDF15 tells the brain to lose weight
p827 | doi:10.1038/nrd.2017.241

Cancer immunotherapy: Rewiring cancer cells
p828 | doi:10.1038/nrd.2017.242



Polypharmacology: Repurposing ceritinib | Infectious disease: Fighting influenza B | Diabetes: Selective FOXO1 modulation | GPCRs: Crystal structure of D4 dopamine receptor

Drug Discovery
JOBS of the week
Principal Scientist in Cellular Pharmacology
Johnson & Johnson
MRC WIMM Prize PhD Studentships
Weatherall Institute of Molecular Medicine, University of Oxford
Postdoctoral, Department of Pharmaceutical Sciences
State University of New York
Tenured Professor Position
Postdoctoral Fellow
Washington University School of Medicine, St. Louis
More Science jobs from
Drug Discovery
20th Annual Superbugs & Superdrugs
London, UK
More science events from
Trends in GPCR drug discovery: new agents, targets and indications
Alexander S. Hauser, Misty M. Attwood, Mathias Rask-Andersen, Helgi B. Schiöth & David E. Gloriam

p829 | doi:10.1038/nrd.2017.178
G protein-coupled receptors (GPCRs) are the most intensively studied class of drug targets. This article presents a pioneering analysis of all GPCR-targeted drugs and agents that are currently in clinical trials, and discusses the trends across molecule types, drug targets and therapeutic indications.
Abstract | Full Text | PDF
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Daniella M. Schwartz, Yuka Kanno, Alejandro Villarino, Michael Ward, Massimo Gadina & John J. O'Shea

p843 | doi:10.1038/nrd.2017.201
Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines. Jakinibs — small-molecule inhibitors of JAKs — have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies. This Review discusses the biology, development and efficacy of jakinibs in the treatment of immune and inflammatory diseases.
Abstract | Full Text | PDF

Tau-based therapies in neurodegeneration: opportunities and challenges
Chuanzhou Li & Jurgen Gotz

p863 | doi:10.1038/nrd.2017.155
Aggregates of the microtubule-associated protein tau are a defining feature of several neurodegenerative disorders, including Alzheimer disease (AD). Given the recent failures of several amyloid-β-targeted therapies for AD, interest is growing in tau as an alternative target, and this Review describes preclinical and clinical studies of tau-based approaches in the light of recent advances in the understanding of the physiological and pathological roles of tau.
Abstract | Full Text | PDF

Poster on: The expanding CRISPR toolbox 

The CRISPR-Cas9 system can do a lot more than gene editing. This Poster, from Nature Methods, explores the newest possibilities of CRISPR.

Available to download free online

Produced with support from: 
npj Precision Oncology is a new open access, online-only, peer-reviewed journal committed to publishing cutting-edge scientific research in all aspects of precision oncology from basic science to translational applications, to clinical medicine.

The journal is part of the Nature Partner Journals series and published in partnership with The Hormel Institute, University of Minnesota.

Explore the benefits of submitting your manuscript
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature